Search Results - "Pottier, V"

Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study by Pivot, X., Spano, J.P., Espie, M., Cottu, P., Jouannaud, C., Pottier, V., Moreau, L., Extra, J.M., Lortholary, A., Rivera, P., Spaeth, D., Attar-Rabia, H., Benkanoun, C., Dima-Martinez, L., Esposito, N., Gligorov, J.

“…HannaH (NCT00950300) and PrefHer (NCT01401166) studies validated the subcutaneous (H-s.c.) formulation of trastuzumab as effective and safe as intravenous…”
Get full text

Successful rituximab therapy in a lupus patient with diffuse alveolar haemorrhage by Pottier, V, Pierrot, M, Subra, J-F, Mercat, A, Kouatchet, A, Parrot, A, Augusto, J-F

“…Diffuse alveolar haemorrhage (DAH) is a rare but life-threatening complication of systemic lupus erythematosus (SLE). Specific therapy is based on a heavy…”
Get full text

Immediate hypersensitivity to platelet concentrate: allergic or not? by Mariotte, D., Bazin, A., Da Silva Costa-Aze, V., Pottier, V., Samba, D., Vergnaud, M.-C., Comby, E., Le Mauff, B., Laroche, D.

Get full text

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication by Schneeweiss, A., Peretz-Yablonski, T., Nowecki, Z., Merot, J.-L., Pena-Murillo, C., Bachelot, T., Coudert, B., Nowecki, Z., Wardley, A., Puglisi, F., Montemurro, F., Hu, X., Gaafar, R., Li, H., Aktas, B., Tienghi, A., Miles, D., Lux, M., Menjon Beltran, S., Turner, N., Tong, Z., Boer, K., Horvath, Z., Susnjar, S., Matos, E., Garcia Estevez, L., Cruz, M., Bourgeois, H., von Schumann, R., Morales-Vásques, F., Voitko, N., Hicks, J., Barrett-Lee, P., Wheatley, D., Gozy, M., Latini, L., Barnadas Molins, A., Bratos, R., McCarthy, N., Kee, D., Artignan, X., Azribi, F., Jaafar, H., Augereau, P., Müller, V., Evron, E., Cascinu, S., El-Saghir, N., Ghosn, M., Oosterkamp, H.M., Kukulska, M., Levitt, N., Panwar, U., Rigg, A., Fein, L., Malik, L., Singer, C., Stoeger, H., Cedeño, M., Berdah, J.-F., Goncalves, A., Orfeuvre, H., Fried, G., Moscetti, L., Siddiqi, N., Arcediano Del Amo, A., McAdam, K., Dunn, G., Taylor, W., Hegg, R., Grosjean, J., Laplaige, P., Christensen, B., Zahm, D.-M., Inbar, M., Bonetti, A., van der Velden, A., van Warmerdam, L., Viñas Vilaro, G., Bachmeier, K., Beresford, M., Joffe, J., Nobre, A., Jiang, J., Padrik, P., Dohollou, N., Prulhiere, K., Ober, A., Alabiso, O., van de Wouw, A.J., Saadein, A., Abdelhafiez, N., Abulkhair, O., Llorente Domenech, R., Gil Raga, M., Rodriguez Sanchez, C., Torrego Garcia, J., Vicente Rubio, E., Jones, A., Alonso, I.

“…The phase III CLinical Evaluation Of Pertuzumab And TRAstuzumab (CLEOPATRA) trial established the combination of pertuzumab, trastuzumab and docetaxel as…”
Get full text

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings by Kubicka, S., André, T., von Moos, R., Österlund, P., Reyes-Rivera, I., Müller, T., Arnold, D., Balcke, P., Benedicic, B., Eisterer, W., Fridrik, M., Samonigg, H., Arts, J., De Man, M., Janssens, J., Benczikova, B., Prausova, J., Vitek, P., Jensen, B.B., Keldsen, N., Østerlind, K., Borg, C., Breysacher, G., Chone, L., Dourthe, L.-M., Faroux, R., Illory, J.F., Lecomte, T., Legoux, J.-L., Levache, B., Lotz, J.-P., Mabro, M., Manfredi, S., Matysiak Budnik, T., Miglianico, L., Pezet, D., Porneuf, M., Tournigand, C., Viret, F., Ychou, M., Bangerter, M., Bertram, M.E., Bohnsteen, B., Cordes, H.-J., Eggert, J., Engel, E., Florschütz, A., Freier, W., Freund, M., Göhler, T., Hagen, V., Hebart, H.F., Heike, M., Höffkes, H.-G., Kettner, E., Kneba, M., Kojouharoff, G., Kretzschmar, A., Kröning, H., Lammert, F., Papke, J., Rädle, J., Ridwelski, K., Rudi, J., Schmalenberger, A., Schwarzer, A., Schwerdtfeger, M., Selbach, J., Staib, P., Stauch, M., Steffens, C.-C., Stübs, P., Tischendorf, J., Tummes, D., Von Wichert, G.P.L., Zomorodbaksch, B., Bloemendal, H.J., Guren, T., Soerbye, H., Fragoso, R., Mellidez, J.C., Darwish, T., Aparicio, J., Aranda, E., Camara, J.C., Donnay, O., Escudero, P., Gallego Plazas, J., Gonzalez Flores, E., Gravalos, C., Guardeno, R., Juárez, A., Massuti Sureda, B., Tobena, M., Toral, J.C., Valenti, V., Berglund, A., Fernebro, E., Hess-Umbricht, V., Popescu, R.

“…ML18147 evaluated continued bevacizumab with second-line chemotherapy for patients with metastatic colorectal cancer (mCRC) progressing after the standard…”
Get full text

Apport diagnostique de la scintigraphie aux plaquettes marquées dans les thrombopénies associées aux syndromes myélodysplasiques by Durand, P., Pottier, V., Mesguich, C., Debordeaux, F., Lazaro, E., Viallard, J.F., Riviere, E.

“…Les thrombopénies sont fréquentes dans les syndromes myélodysplasiques (SMD), et leur traitement varie selon leur mécanisme. Elles peuvent être dues à un…”
Get full text

Patient preference of trastuzumab administration (SC versus IV) in HER2-positive metastatic breast cancer: Results of the randomised Metaspher study by Pivot, X., Spano, J.-P., Marc, E., Cottu, P., Jouannaud, C., Pottier, V., Moreau, L., Extra, J.-M., Lortholary, A., Rivera, P., Spaeth, D., Attar-Rabia, H., Benkamoun, C., Dima-Martinez, L., Esposito, N., Gligorov, J.

Get full text

39. Dosimetric study of medical staff for selective internal radiation therapy using 90 Y glass microsphere for the treatment of hepatic cancer by Ralite, F., Herit, S., Briceno, P., Kantor, G., Cazeau, A.L., Stein, Ph, Pottier, V., Lortal, B., Catena, V., Buy, X., Palussière, J., Caron, J.

Get full text

39. Dosimetric study of medical staff for selective internal radiation therapy using 90Y glass microsphere for the treatment of hepatic cancer by Ralite, F., Herit, S., Briceno, P., Kantor, G., Cazeau, A.L., Stein, Ph, Pottier, V., Lortal, B., Catena, V., Buy, X., Palussière, J., Caron, J.

“…Selective internal radiation therapy using 90Y glass microsphere is a treatment dedicated to non-resectable hepatic tumours. This technique requires two…”
Get full text

Optimisation de la conservation d’une seringue de 99mTc-examétazime (protocole épilepsie : injection ictale) by Beaurain, M., Salabert, A.S., Pottier, V., Alonso, M., Tafani, J.A.

“…Le 99mTc-examétazime (Cerestab®) est un médicament radiopharmaceutique (MRP) utilisé lors de scintigraphies de perfusion cérébrale pour la recherche…”
Get full text

Nouveau cas d'hépatite aiguë de type E en France by Dupuy, O, Mayaudon, H, Bauduceau, B, Perrier, E, Nizou, C, Pottier, V, Buisson, Y

Get full text

Immediate hypersensitivity to platelet concentrate: allergic or not? by Mariotte, D, Bazin, A, Da Silva Costa-Aze, V, Pottier, V, Samba, D, Vergnaud, M-C, Comby, E, Le Mauff, B, Laroche, D

Get full text

A new case of acute hepatitis type E in France by Dupuy, O, Mayaudon, H, Bauduceau, B, Perrier, E, Nizou, C, Pottier, V, Buisson, Y

Get full text

A new case of acute hepatitis type E in France by Dupuy, O, Mayaudon, H, Bauduceau, B, Perrier, E, Nizou, C, Pottier, V, Buisson, Y

Get full text